148 Increasing to weekly adalimumab dosing leads to improved psoriasis outcomes-a retrospective single centre review of real-world data

Abstract

Adalimumab is a well-tolerated and effective biologic treatment for psoriasis. Given its efficacy and biosimilar availability, it is often a first-line biologic. Clinical trial data have demonstrated that dose escalation from fortnightly to weekly is an effective and safe strategy. However, real-world data is lacking; therefore we aimed to assess patient response to dose escalation in the clinical setting. We reviewed records of patients treated with weekly adalimumab between January 2018-May 2022.